Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06128629 · ClinicalTrials.gov registry record · Phase 3
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
A Phase 3 study of Transthyretin Amyloidosis (ATTR) With Cardiomyopathy, sponsored by Intellia Therapeutics.
- Active
- Registry status
- Phase 3
- Development phase
- 1,200
- Enrollment target
- 20
- Study locations
NCT06128629 is a Phase 3 study of Transthyretin Amyloidosis (ATTR) With Cardiomyopathy that is active but no longer recruiting, run by Intellia Therapeutics. The registered enrollment target is 1,200 participants. The trial reports 20 study locations across 15 states.
The verdict
NCT06128629, a Phase 3 study of Transthyretin Amyloidosis (ATTR) With Cardiomyopathy, is active but no longer recruiting, sponsored by Intellia Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,200 participants
- Enrollment target
- 20
- Study locations
Study Summary
To evaluate the efficacy and safety of a single dose of NTLA-2001 compared to placebo in participants with ATTR-CM.
Conditions Studied
Interventions
- DRUG Placebo
- BIOLOGICAL NTLA-2001
Study Locations (20)
California
- Cedars-Sinai Medical Center - Los Angeles
- Western Greater Los Angeles VA Medical Center - Los Angeles
- Stanford University - Palo Alto
- University of California, San Diego (UCSD) - Medical Center - San Diego
Florida
- Mayo Clinic - Jacksonville - Jacksonville
- Cleveland Clinic of Florida - Weston
Massachusetts
- Brigham and Women's Hospital - Boston
- Boston University School of Medicine - Boston
Arizona
- University of Arizona - Tucson
Colorado
- University of Colorado Denver - Denver
Connecticut
- Yale University School of Medicine - New Haven
District of Columbia
- MedStar Washington Hospital Center - MedStar Heart and Vascular Institute - Washington D.C.
Georgia
- Emory University School of Medicine - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,200 participants |
| Start Date | 2023-12-13 |
| Est. Completion | 2028-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06128629
The ClinicalTrials.gov registry entry for NCT06128629 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Intellia Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Transthyretin Amyloidosis (ATTR) With Cardiomyopathy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06128629 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06128629 about?
NCT06128629 is a clinical study titled "MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)". To evaluate the efficacy and safety of a single dose of NTLA-2001 compared to placebo in participants with ATTR-CM.
What is the current status of trial NCT06128629?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,200 participants. The study started on 2023-12-13. Estimated completion is 2028-04.
What conditions does trial NCT06128629 study?
This clinical trial studies the following conditions: Transthyretin Amyloidosis (ATTR) With Cardiomyopathy.
What interventions are being tested in trial NCT06128629?
The interventions under investigation include: Placebo (DRUG), NTLA-2001 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06128629?
This trial is sponsored by Intellia Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06128629 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
ACTIVE NOT RECRUITING · Phase 3
-
APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.